Fujirebio

Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD). The company focuses on developing new technologies and unique biomarkers with high clinical value, aiming to create new value in healthcare and contribute to human health and the future of medical care. With global teams located in Japan, Asia, Europe, and the US, Fujirebio prioritizes delivering products with the highest quality standards to customers and partners. The company values partnerships with other leading companies in the industry, aiming to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms to meet the largest global need in the shortest possible time.

Fujirebio has a strong tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Established in 1950 in Tokyo, Japan, Fujirebio has over the years concluded successful acquisitions of best-in-class IVD companies, including Centocor Diagnostics in 1998, CanAg Diagnostics in 2006, and Innogenetics in 2010. The company's global presence includes offices in the United States, Latin America, Europe, and Asia, as well as a vast international distribution network. As a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544), Fujirebio employs more than 1,200 people in Asia, Europe, and America.